BPC-157

A synthetic 15-amino-acid peptide derived from human gastric juice protein, studied for tissue-healing and cytoprotective properties.

Profile · 01

Overview

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from human gastric juice protein, studied for tissue-healing and cytoprotective properties. It is not FDA-approved for any indication.

Preclinical models show accelerated wound repair and anti-inflammatory activity, though human clinical data remain limited to early-phase safety trials and small case reports. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Support tissue repair, gut healing, and recovery processes
Categories
Tissue RepairRecoveryGut HealthAnti-Inflammatory
Synergistic
TB-500 (Thymosin Beta-4) · GHK-Cu · Collagen Peptides
Profile · 02

Protocol

Suggested daily titration approach starting low and increasing every two weeks.

Typical daily range
200–600 mcg once daily (gradual titration)
Start
200 mcg daily; increase by ~200 mcg every 2 weeks as tolerated
Target
400–600 mcg daily by Weeks 5–8+
Frequency
Once per day (subcutaneous)
Cycle Length
8–12 weeks; optional extension to 16 weeks
Timing
Any consistent time; rotate injection sites
Route
Subcutaneous
Cycle
8–12 weeks on, 4 weeks off

Inject once daily subcutaneously using the largest practical dilution to maintain measurement accuracy. Dosing extrapolates from preclinical models; human clinical validation remains limited.

Dose progression

Weeks 1–2
200 mcg (0.2 mg)
Weeks 3–4
400 mcg (0.4 mg)
Weeks 5–8+
600 mcg (0.6 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How BPC-157 works.

BPC-157 corresponds to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues.

Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries. A Phase I oral safety trial has been completed, and a small human case series reported improvements following intra-articular administration; however, large-scale controlled human efficacy data remain unavailable.

Science · 02

Effects

Observations from clinical or preclinical literature.

Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data)
Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings
May support gut lining integrity and gastric ulcer healing (preclinical, under investigation)
Phase I safety studies report good tolerability with no serious adverse events at tested doses
Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration
Long-term human safety and efficacy remain under investigation
Science · 03

Caution

Individuals with active cancer or a history of cancer should avoid use due to BPC-157's pro-angiogenic properties
Not recommended during pregnancy or breastfeeding (no safety data available)
Use with caution if taking anticoagulants or medications affecting blood clotting
Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Zinc
Supports wound healing and immune function; commonly depleted in tissue injury.
Vitamin C
Essential cofactor for collagen synthesis and tissue repair.
Magnesium
Supports enzymatic processes involved in tissue recovery.
Omega-3 fatty acids
Support anti-inflammatory pathways complementary to BPC-157's mechanisms.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Support recovery with adequate protein intake and micronutrient-rich foods
Balance activity and rest to allow tissue adaptation without overuse
Prioritize sleep and stress management to enhance natural healing processes
Consult qualified healthcare providers for injury-specific rehabilitation guidance
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Pain levels and functional mobility — monitor changes in the target area to gauge healing response
  2. Inflammation markers (subjective swelling, redness, heat) — track daily to identify trends
  3. Sleep quality and recovery perception — poor sleep impairs healing; track to ensure adequate rest
  4. Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)
General inflammation marker; track before and during protocol.
ESR (Erythrocyte Sedimentation Rate)
Secondary inflammation marker to corroborate CRP trends.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry
Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly; wait a few seconds before withdrawing the needle
Document daily dose and site rotation to maintain consistency
BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. Journal of Pharmacological Sciences
    Klicek R et al., "BPC-157 promotes colocutaneous fistula healing via NO-system modulation (rat model)".
    https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_article
  2. Pharmaceuticals (MDPI, 2025)
    Jozwiak M et al., "Multifunctionality and possible medical application of BPC-157: literature and patent review".
    https://www.mdpi.com/1424-8247/18/2/185
  3. Current Pharmaceutical Design (PMC)
    Sikiric P et al., "BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing and tissue repair".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
  4. Life Sciences
    Seiwerth S et al., "BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond".
    https://pubmed.ncbi.nlm.nih.gov/29990514/
  5. HSS Journal (PubMed, 2025)
    Vasireddi N et al., "Emerging use of BPC-157 in orthopaedic sports medicine: systematic review".
    https://pubmed.ncbi.nlm.nih.gov/40756949/
  6. Journal of Orthopaedic Research
    Chang CH et al., "BPC-157 promotes tendon-to-bone healing in a rat rotator cuff model".
    https://pubmed.ncbi.nlm.nih.gov/32710582/
  7. WHO (NCBI Bookshelf, 2016)
    Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings.
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
  8. Johns Hopkins Arthritis Center
    How to give a subcutaneous injection (patient education resource).
    https://www.hopkinsarthritis.org/patient-corner/how-to-give-a-subcutaneous-injection/
  9. ClinicalTrials.gov
    NCT02637284: PCO-02 Phase I safety and pharmacokinetics trial of oral BPC-157.
    https://clinicaltrials.gov/ct2/show/NCT02637284
  10. CDC
    Vaccine administration: subcutaneous route (angle/site; no aspiration).
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  11. Subcutaneous Drug Injection Review (PMC)
    Pharmacologic considerations of the subcutaneous route.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
  12. World Journal of Gastroenterology (PMC)
    Sikiric P et al., "Pentadecapeptide BPC-157: from GI tract to whole body healing".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6163624/
On this page